Search Results

Displaying Results 1-2 of 2 "'RZB'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

patients with moderate plaque psoriasis receiving risankizumab (RZB) compared with deucravacitinib (DEU) will be presented. Results demonstrated that patients with higher levels of skin clearance (PASI 90 [RZB 57.3% vs DEU 22.9%] and PASI 100 [RZB 27.5% vs DEU 6.5%]), had greater resolution of psoriasis symptoms

More news about: AbbVie

Mar 02, 2026, 08:30 ET AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

RZB SCPBORZB SC

More news about: AbbVie

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.